Healthcare / BiotechnologyASX
$0.01
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 12%
FCF escenarios
weak_data · normalized FCF $-4.6M · quality 29.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
3/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-581.1%
↓Gross Margin
100.0%
↑Debt/Equity
3.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.5%
FCF CAGR
—
FCF margin
-460.2%
FCF / Net income
0.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.2M · net income $-5.9M · FCF $-5.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.2M | $1.2M | $5.1M | $8.4M | $1.7M |
| Net Income | $-5.9M | $-5.9M | $-5.8M | $-764000.00 | $-9.8M |
| EBITDA | $-5.2M | $-5.2M | $-8.1M | $-2.8M | $-12.3M |
| EPS | -0.02 | -0.02 | -0.02 | -0.00 | -0.03 |
| Gross Margin | 100.0% | 100.0% | 22.3% | 93.4% | 100.0% |
| Operating Margin | -753.9% | -753.9% | -168.4% | -40.2% | -754.3% |
| Net Margin | -499.6% | -499.6% | -113.9% | -9.1% | -572.1% |
| Balance Sheet | |||||
| Debt/Equity | 3.55 | 3.55 | 1.13 | 0.27 | 0.23 |
| Current Ratio | 1.35 | 1.35 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.5M | $-5.5M | $-4.6M | $584000.00 | $-9.3M |
| Returns | |||||
| ROE | -581.1% | -581.1% | -177.0% | -8.8% | -108.2% |
| Valuation | |||||
| P/B | 4.13 | 4.13 | 5.57 | 1.65 | 1.62 |
| Growth & Yield | |||||
| Revenue Growth | -76.6% | -76.6% | -39.6% | 390.3% | — |
| EPS Growth | 15.5% | 15.5% | -640.7% | 92.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-47.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.02
Residual
-47.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.